EBD-GROUP
BIO-Europe® 2014 international partnering conference will take place November 3–5 in Frankfurt, Germany, at the Portalhaus Messe Frankfurt conference center. BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.
The conference will kick off with keynote addresses by Andreas Busch, Member, Executive Committee, Head, Global Drug Discovery, Bayer HealthCare; David Loew, Senior VP, Commercial Operations, Europe, Sanofi; and Luciano Rossetti, Executive VP, Head of Global Research and Development, Member of the Pharmaceutical Executive Committee, Merck Serono. The keynote will be followed by their participation in an Opening Plenary Discussion entitled “Biopharma strategy: More focus, more value?” moderated by Jean-François Formela , Partner, Atlas Venture.
A keynote plenary discussion entitled “A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2014” will headline the second day of the conference. The keynote plenary will be moderated by Evonne Sepsis , Founder and Managing Director at ESC Advisors and David Stubbs , Founding Partner and Managing Director at Inverness Advisors. The featured panelists are Iain Dukes , Senior VP, Business Development and Licensing at Merck; Shaun Grady , VP, Business Development Operations, AstraZeneca; Adam Keeney , Global Head, External Innovation Operations Strategy, Science Policy and External Innovation, Sanofi; and James Sabry , Senior VP, Global Head of Partnering, Genentech.
“The most compelling aspect of the BIO-Europe keynote plenary topic is sharing reflections on various transformational deals taking place across the industry and unpacking what makes them game-changers,” said Grady. “We’ll discuss what makes a deal within our industry truly transformational, highlighting innovation in the deal structure and the linkage with R&D strategy, assessing commercial potential, and securing and incentivizing the commitment of partners involved. The magic is very often in the details.”
“In thinking about deals at Sanofi, we focus on the opportunities that have the ability to deliver transformational solutions that can significantly benefit the patient,” said Keeney . “Because in the end, deals that transformed the market were those that were open to a paradigm shift in their thinking about disease, and in the way they structured their R&D to remain innovative. I think this bears on our discussion at BIO-Europe.”
Other highlights of the BIO-Europe program include dual track Parallel Panel Discussions. In the Business Development Track, topics range from access to medicines in late-stage clinical trials to funding for EU companies, early market access and sell-side dealmakers. The Spotlight Track features topics ranging from late stage complications in diabetes and next-generation cancer therapies and immunotherapies, to corporate views on personalized immune intervention and advancements in orphan drugs.
In addition, the afternoon will feature Pharmaceutical company presentations from the many pharma companies confirmed to send business development teams to BIO-Europe 2014. They include AbbVie; Alexion Pharmaceuticals; Amgen; AstraZeneca; Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Licensing; Bristol-Myers Squibb; Daiichi Sankyo Co., Ltd.; Eli Lilly and Company; Genentech; GlaxoSmithKline; Janssen Pharmaceutical Companies of Johnson & Johnson; Merck Serono; MSD; Novartis; Novo Nordisk; Pfizer; Roche; Sanofi; and Takeda.
At BIO-Europe, companies participate in one-to-one partnering meetings facilitated by EBD Group’s highly reputable partneringONE® platform.
The 2013 edition featured 17,874 one-to-one partnering meetings, an all-time record. Over 3,200 delegates from 1,841 companies representing 56 countries attended. There were 184 company presentations with close to 3,600 licensing opportunities on offer, and 95 exhibitors at the event.
Registration information is available on the BIO-Europe web site for Europe’s largest partnering conference serving the global biotechnology industry.
About BIO-Europe ® 2014:
The 20th annual BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry.
Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships.
Follow BIO-Europe 2014 on Twitter: twitter.com/ebdgroup (hashtag: No. BEU14). Or log on to the Life Science Partnering discussion forum on partnering360. The Group is your go-to discussion forum for news and topics related to BIO-Europe.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe ® and BIO-Europe Spring ®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America ™, the fastest growing partnering event in North America
- Biotech Showcase ™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe , the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum , the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech ™, EBD Group’s partnering event for the innovative medical technology industry
- The Global Impact Forum ™, a unique and innovative partnering conference in impact investing and venture philanthropy.
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141016005083/en/
Contact:
EBD Group
Erin Righetti, +1-760-930-0500
erighetti@ebdgroup.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
PPG celebrates 3,000th installation of PPG MOONWALK paint mixing system at U.S. collision center14.8.2025 20:01:00 CEST | Press release
PPG (NYSE: PPG) today announced that it has completed the 3,000th global installation of its PPG MOONWALK® automated paint mixing system at Wren’s Collision Group’s facility in Auburn, Ala. Since its launch in 2019, the PPG MoonWalk system has transformed body shop operations worldwide by delivering exceptional accuracy, traceability and productivity across the automotive repair process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814323910/en/ “We are proud to be a part of this innovation in the automotive industry with the installation of the 3,000th PPG MoonWalk system at our newest body shop,” said James Wren, owner of Wren’s Collision Group, at a celebration of the milestone held in July. “With our new Auburn facility, we are looking forward to continuing to drive productivity, efficiency, and profit throughout the 19 body shops we own. We are excited to be a part of this milestone for PPG as a long-standing partn
Xsolla Expands Payment Coverage in Europe to Unlock New Market Potential for Game Developers With Bizum, Swish, and Satispay14.8.2025 18:00:00 CEST | Press release
New Payment Methods Give Game Developers Localized, Mobile-First Checkout Options In Spain, Sweden, And Italy Xsolla, a global commerce company helping developers launch, grow and monetize their games, announces today the expansion of its payments solution across Europe with the launch of new regionally preferred methods: Bizum in Spain, Swish in Sweden, and Satispay in Italy. These integrations via Xsolla Pay Station enable game developers and publishers to offer secure, seamless, and familiar checkout flows across three of the region’s fastest-growing digital economies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814474025/en/ (Graphic: Xsolla) The European gaming market is expected to generate nearly $85 billion in 2025 and grow to over $112 billion by 2029. As mobile and app-native payment preferences continue to rise globally, players are increasingly demanding fast, secure, and culturally aligned payment options.
Eurazeo Enters Into Exclusive Discussions With INSPIRED PET NUTRITION Regarding the Sale of Its Stake in Ultra Premium Direct14.8.2025 17:40:00 CEST | Press release
Eurazeo has entered into exclusive discussions with INSPIRED PET NUTRITION (“IPN”), the fast-growing international pet food company controlled by CapVest Partners LLP (“CapVest”), regarding the sale of Ultra Premium Direct (“UPD”), France’s leading direct-to-consumer (D2C) online pet food company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814809542/en/ Ultra Premium Direct product Founded in 2013, UPD has established itself as a leading player in the French premium pet food market and is now recognised as the top direct-to-consumer (D2C) online brand in the segment, recognised for its exceptional customer experience and already serving over 285k active customers. UPD combines high-quality, veterinarian-developed products with a direct factory-to-consumer model, offering a unique premium yet affordable proposition. Leveraging its data-driven approach, the company is now building a powerful omnichannel strategy to furt
Tyk Scales up in US Financial Sector, as Banks Lean on APIs as Revenue-Driving Infrastructure14.8.2025 17:24:00 CEST | Press release
AI-ready API management company Tyk has announced the appointment of three new senior leaders, as it strengthens its support for banks in the US financial sector. The strategic appointments come as banks increasingly evolve their use of APIs towards monetization. Martin Buhr, Founder and CEO of Tyk, which specializes in providing practical blueprints for integrating AI in a way that’s well-governed, efficient, and future-ready, explains: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814736978/en/ Tyk scales up in US financial sector “Just a couple of years ago, banks were coming to us focused on basic authentication and control requests. Now, it’s becoming the norm for them to use APIs to underpin new monetization strategies, as well as seamless regulatory compliance. We’ve helped leading global banks make the change and are excited to have three API industry veterans – Mark Gurvis, Laura Heritage and Kuldeepak Angrish –
LambdaTest Unveils Media Injection for Real Device Testing14.8.2025 17:00:00 CEST | Press release
Innovative camera simulation feature enables robust testing of image and video capture workflows across 10,000+ real mobile devices LambdaTest, a unified agentic AI and cloud engineering platform, has launched Video Injection capability in Media Injection for real device testing, bringing powerful support for testing camera and video-based app functionalities at scale. This new capability empowers developers and QA teams to simulate image and video capture scenarios on real Android and iOS devices, unlocking comprehensive validation for camera-driven app experiences. With Media Injection, users can test key workflows like QR code and barcode scanning, digital check processing, real-time video streaming, and photo or video upload features, directly on physical devices. This is made possible through LambdaTest’s proprietary Sensor Instrumentation technology, which seamlessly injects simulated media into the app’s camera interface, bypassing the need for physical camera use while ensuring
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum